Biologics get the headlines, but small molecules (pills, not injections) still dominate drug discovery. The small molecule drug discovery market report by MRFR shows that oncology is the largest therapeutic area, but neurological disorders are the fastest‑growing. The market is $74.08 billion and will hit $191.2 billion by 2035, growing at 9.0% CAGR. Why the resilience? Because pills are cheap to manufacture, easy to take, and can cross the blood‑brain barrier.

What's driving growth? Enzymes are the largest target type, but receptors are the fastest‑growing. The small molecule drug discovery market analysis highlights that high‑throughput screening is the largest technology, but structure‑based drug design is the fastest‑growing — as computational power increases.

What's new? AI‑powered drug design platforms that predict how a molecule will bind to its target, before it's ever synthesized. That cuts years off development.

The bottom line: small molecules aren't going away. They're getting smarter. And with AI, we're discovering drugs for diseases that were untouchable before.